Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Schwab

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Jun 14, 2021 6:10pm

138 Views

Post# 33385857

RE:RE:RE:RE:RE:RE:Schwab

Wino115 wrote:
Any milestones that bring the magnitude of likely revenues into sight will create the step function upward we've seen in other biotechs. We just need a moderate sized audience that gets it and hopefully the IR plan creates it. Milestones will help that too.

qwerty22 wrote:

Milestones

palinc2000 wrote: I think you are giving too much weight LSA s impact ,,,The best promoter for the stock is THTX and its CEO,,,LSA does not have a magic wand ,,,,Hopefully they will add strength to an upswing in the stock price but something is needed to ignite the fire and thats management s job